Urolithiasis associated with topiramate

AUTOR(ES)

Eggener, Scott, Kim, Samuel C., User, Herbert M., Pazona, Joseph, Nadler, Robert B.

FONTE

International braz j urol

DATA DE PUBLICAÇÃO

2004-02

RESUMO

OBJECTIVE: Topiramate is a sulfamate-substituted monosaccharide anticonvulsant used as adjunctive therapy for intractable refractory seizures. It is report a case of topiramate-induced urolithiasis. CASE REPORT: A 35-year-old man presented with acute, right-sided, colicky flank pain. He denied hematuria or dysuria. He was in use of phenytoin, risperidone, phenobarbital, and topiramate. The total daily dose of topiramate was 375 mg. A CT scan showed a 7 x 1 mm curvilinear density at the right ureterovesical junction with proximal hydrouretronephrosis. He was managed with rigid ureteroscopic stone extraction and the calculus metabolic analysis revealed the stone was composed of carbonate apatite (70%), calcium oxalate dihydrate (20%), and calcium oxalate monohydrate (10%). COMMENTS: The present case typifies many features of topiramate-induced urolithiasis. Those who care for patients with urinary stone disease should be aware of this association.

Documentos Relacionados

• Modafinil Treatment of Excessive Daytime Sedation and Fatigue Associated With Topiramate
• Transient hemiparesis with topiramate
• Ureteroinguinal hernia with obstructive urolithiasis
• Are patients with lichen planus really prone to urolithiasis? Lichen planus and urolithiasis
• Metabolic assessment of elderly men with urolithiasis